JARED ELLIS: Open Payments
NPI 1790785756 · TUSCALOOSA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 23 payments from 9 companies in 2025. Trend: 2023 $3,010 · 2024 $1,861 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $189 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| ABBVIE INC. | 3 | $48 |
| Octapharma USA, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| PFIZER INC. | 1 | $15 |
Products named: CAPLYTA, REXULTI, Auvelity, QULIPTA, PANZYGA, INGREZZA, Wegovy, NURTEC ODT.
Industry payments across AL — which companies pay providers there.
